Natsayi Chimbindi1, Jacob Bor, Marie-Louise Newell, Frank Tanser, Rob Baltussen, Jan Hontelez, Sake J de Vlas, Mark Lurie, Deenan Pillay, Till Bärnighausen. 1. *Wellcome Trust Africa Centre for Health and Population Studies, University of KwaZulu-Natal, South Africa; †School of Public Health, University of the Witwatersrand, Johannesburg, South Africa; ‡Department of Global Health, School of Public Health, Boston University, Boston, MA; §Faculty of Medicine and Faculty of Human and Social Sciences, University of Southampton, Southampton, United Kingdom; ‖Nijmegen International Center for Health System Analysis and Education (NICHE), Department of Primary and Community Care, Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands; ¶Department of Public Health, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands; #Department of Epidemiology and International Health Institute, Brown University School of Public Health, Providence, RI; **Department of Virology, University College London, London, United Kingdom; and ††Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, MA.
Abstract
BACKGROUND: HIV and tuberculosis (TB) services are provided free of charge in many sub-Saharan African countries, but patients still incur costs. METHODS: Patient-exit interviews were conducted in primary health care clinics in rural South Africa with representative samples of 200 HIV-infected patients enrolled in a pre-antiretroviral treatment (pre-ART) program, 300 patients receiving antiretroviral treatment (ART), and 300 patients receiving TB treatment. For each group, we calculated health expenditures across different spending categories, time spent traveling to and using services, and how patients financed their spending. Associations between patient group and costs were assessed in multivariate regression models. RESULTS: Total monthly health expenditures [1 USD = 7.3 South African Rand (ZAR)] were ZAR 171 [95% confidence interval (CI): 134 to 207] for pre-ART, ZAR 164 (95% CI: 141 to 187) for ART, and ZAR 122 (95% CI: 105 to 140) for TB patients (P = 0.01). Total monthly time costs (in hours) were 3.4 (95% CI: 3.3 to 3.5) for pre-ART, 5.0 (95% CI: 4.7 to 5.3) for ART, and 3.2 (95% CI: 2.9 to 3.4) for TB patients (P < 0.01). Although overall patient costs were similar across groups, pre-ART patients spent on average ZAR 29.2 more on traditional healers and ZAR 25.9 more on chemists and private doctors than ART patients, whereas ART patients spent ZAR 34.0 more than pre-ART patients on transport to clinics (P < 0.05 for all results). Thirty-one percent of pre-ART, 39% of ART, and 41% of TB patients borrowed money or sold assets to finance health care. CONCLUSIONS: Patients receiving nominally free care for HIV/TB face large private costs, commonly leading to financial distress. Subsidized transport, fewer clinic visits, and drug pick-up points closer to home could reduce costs for ART patients, potentially improving retention and adherence. Large expenditure on alternative care among pre-ART patients suggests that transitioning patients to ART earlier, as under HIV treatment-as-prevention policies, may not substantially increase patients' financial burden.
BACKGROUND: HIV and tuberculosis (TB) services are provided free of charge in many sub-Saharan African countries, but patients still incur costs. METHODS: Patient-exit interviews were conducted in primary health care clinics in rural South Africa with representative samples of 200 HIV-infected patients enrolled in a pre-antiretroviral treatment (pre-ART) program, 300 patients receiving antiretroviral treatment (ART), and 300 patients receiving TB treatment. For each group, we calculated health expenditures across different spending categories, time spent traveling to and using services, and how patients financed their spending. Associations between patient group and costs were assessed in multivariate regression models. RESULTS: Total monthly health expenditures [1 USD = 7.3 South African Rand (ZAR)] were ZAR 171 [95% confidence interval (CI): 134 to 207] for pre-ART, ZAR 164 (95% CI: 141 to 187) for ART, and ZAR 122 (95% CI: 105 to 140) for TB patients (P = 0.01). Total monthly time costs (in hours) were 3.4 (95% CI: 3.3 to 3.5) for pre-ART, 5.0 (95% CI: 4.7 to 5.3) for ART, and 3.2 (95% CI: 2.9 to 3.4) for TB patients (P < 0.01). Although overall patient costs were similar across groups, pre-ART patients spent on average ZAR 29.2 more on traditional healers and ZAR 25.9 more on chemists and private doctors than ART patients, whereas ART patients spent ZAR 34.0 more than pre-ART patients on transport to clinics (P < 0.05 for all results). Thirty-one percent of pre-ART, 39% of ART, and 41% of TB patients borrowed money or sold assets to finance health care. CONCLUSIONS: Patients receiving nominally free care for HIV/TB face large private costs, commonly leading to financial distress. Subsidized transport, fewer clinic visits, and drug pick-up points closer to home could reduce costs for ART patients, potentially improving retention and adherence. Large expenditure on alternative care among pre-ART patients suggests that transitioning patients to ART earlier, as under HIV treatment-as-prevention policies, may not substantially increase patients' financial burden.
Authors: Myron S Cohen; Ying Q Chen; Marybeth McCauley; Theresa Gamble; Mina C Hosseinipour; Nagalingeswaran Kumarasamy; James G Hakim; Johnstone Kumwenda; Beatriz Grinsztejn; Jose H S Pilotto; Sheela V Godbole; Sanjay Mehendale; Suwat Chariyalertsak; Breno R Santos; Kenneth H Mayer; Irving F Hoffman; Susan H Eshleman; Estelle Piwowar-Manning; Lei Wang; Joseph Makhema; Lisa A Mills; Guy de Bruyn; Ian Sanne; Joseph Eron; Joel Gallant; Diane Havlir; Susan Swindells; Heather Ribaudo; Vanessa Elharrar; David Burns; Taha E Taha; Karin Nielsen-Saines; David Celentano; Max Essex; Thomas R Fleming Journal: N Engl J Med Date: 2011-07-18 Impact factor: 91.245
Authors: Larissa Jennings; Muthoni Mathai; Sebastian Linnemayr; Antonio Trujillo; Margaret Mak'anyengo; Brooke E E Montgomery; Deanna L Kerrigan Journal: AIDS Behav Date: 2017-09
Authors: Karl W Le Roux; Emily C Davis; Charles Benjamin Gaunt; Catherine Young; Maryann Koussa; Carl Harris; Mary Jane Rotheram-Borus Journal: AIDS Patient Care STDS Date: 2019-11 Impact factor: 5.078
Authors: Hyejeong Shin; Lucky G Ngwira; Austin Tucker; Richard E Chaisson; Elizabeth L Corbett; David W Dowdy Journal: Trop Med Int Health Date: 2020-02-28 Impact factor: 3.918
Authors: Jacob Bor; Calvin Chiu; Shahira Ahmed; Ingrid Katz; Matthew P Fox; Sydney Rosen; Manisha Yapa; Frank Tanser; Deenan Pillay; Till Bärnighausen Journal: Trop Med Int Health Date: 2018-01-10 Impact factor: 3.918
Authors: Pascal Geldsetzer; H Manisha N Yapa; Maria Vaikath; Osondu Ogbuoji; Matthew P Fox; Shaffiq M Essajee; Eyerusalem K Negussie; Till Bärnighausen Journal: J Int AIDS Soc Date: 2016-04-25 Impact factor: 5.396